Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Definitions

• the present invention relates to a novel process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcycl opropane hydrochloride, which is useful as an antidepresent, and the reaction product of (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-hydroxymeth ylcyclopropane an orthoester and a br ⁇ nsted acid which is an iminium salt of formula (I) as an intermediate thereof.
• (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalim idomethylcyclopropane (hereafter, may be referred to as the (Z)-phthalimidomethylcyclopropane compound) is an intermediate of a (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcycl opropane hydrochloride (hereafter, (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcycl opropane may be sometimes referred to as the (Z)-aminomethylcyclopropane compound, and (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-aminomethylcycl opropane hydrochloride may be sometimes referred to as the (Z)-aminomethylcyclopropane compound hydrochloride, respectively), which is useful as
• An object of the present invention is to provide a process for producing the (Z)-phthalimidomethylcyclopropane compound and further the (Z)-aminomethylcyclopropane compound hydrochloride at high yield by a simple operation without using a reagent which may generate sulfur dioxide, such as, thionyl chloride, and a low boiling point halogenated hydrocarbon solvent.
• the present invention is as follows.
• the process for producing the (Z)-phthalimidomethylcyclopropane compound of the present invention includes the first step wherein the (Z)-hydroxymethylcyclopropane compound is reacted with an orthoester and a br ⁇ nsted acid selected from methanesulfonic acid, toluenesulfonic acid, trifluoromethanesulfonic acid, sulfuric acid and hydrogen chloride (hereinafter referred to as a br ⁇ nsted acid of the invention) to produce an iminium salt (hereafter, may be referred to as the iminium salt (I)) of the formula (I): wherein A - represents conjugated base of a br ⁇ nsted acid as described above, and the second step wherein the iminium salt (I) is reacted with a phthalimidating agent.
• a br ⁇ nsted acid selected from methanesulfonic acid, toluenesulfonic acid, trifluoromethanesulfonic acid, sulfuric acid and hydrogen chloride
• the first step can be conducted, for example, by mixing the (Z)-hydroxymethylcyclopropane compound, an orthoester and a br ⁇ nsted acid of the invention in a solvent.
• an addition order is not particularly limited, a method of adding an orthoester to the (Z)-hydroxymethylcyclopropane compound and then adding a br ⁇ nsted acid is preferable.
• the orthoester is not particularly limited and easily available ones can be used. Examples thereof include orthofonnicacid alkyl esters (such as trimethyl orthoformate and triethyl orthoformate), orthoaceticacid alkyl esters (such as trimethyl orthoacetate and triethyl orthoacetate), orthobutyricacid alkyl esters (such as trimethyl orthobutyrate and triethyl orthobutyrate) and orthobenzoicacid alkyl esters (such as trimethyl orthobenzoate and triethyl orthobenzoate), among which orthoformicacid alkyl esters are preferable, and trimethyl orthoformate and triethyl orthoformate are more preferable.
• orthofonnicacid alkyl esters such as trimethyl orthoformate and triethyl orthoformate
• orthoaceticacid alkyl esters such as trimethyl orthoacetate and triethyl orthoacetate
• orthobutyricacid alkyl esters such as trimethyl orthobutyrate and triethyl ortho
• the amount of the orthoester is preferably from 1 to 10 g equivalents based on 1 g equivalent of the (Z)-hydroxymethylcyclopropane compound, and more preferably from 1.2 to 2 g equivalents, in view of prevention of generation of material residues or by-products, and reaction efficiency.
• the br ⁇ nsted acids used in the invention are easily available.
• Methanesulfonic acid is preferable in view of reactivity.
• the amount of the br ⁇ nsted acid is preferably from 1 to 10 g equivalents based on 1 g equivalent of the (Z)-hydroxymethylcyclopropane compound, and more preferably from 1 to 1.5 g equivalents, in view of completion of the reaction or reaction efficiency.
• the first step can generally be conducted in a solvent, and an orthoester can also serve as the solvent.
• the solvent is not limited as long as it does not inhibit the reaction, and hydrocarbon solvents such as toluene and aprotic polar solvents such as N, N-dimethylformamide can be used alone or in combination.
• the amount of the solvent is preferably 5 parts by weight or less based on 1 part by weight of the (Z)-hydroxymethylcyclopropane compound.
• the reaction temperature of the first step is generally from 0 to 100°C, and preferably from 20 to 40°C.
• the reaction time is generally from 1 to 24 hours, and preferably from 1 to 10 hours.
• the iminium salt (I), its counter ion is conjugated base of the used br ⁇ nsted acid, is contained.
• the reaction mixture as it is, can be used for the second step.
• the first step and the second step can be conducted in the same reaction vessel, so called in one-pot. In such a case, before the second step, the reaction mixture after completion of the first step can be concentrated and substituted by another solvent.
• the iminium salt (I) can be isolated by removing the solvent under reduced pressure, and may be optionally purified by conventional means such as decantation with an organic solvent or chromatography.
• the iminium salt (I) produced in the first step is a novel compound, and a useful synthetic intermediate of the (Z)-aminomethylcyclopropane compound hydrochloride as an antidepresent.
• a - in the iminium salt (I) is preferably CH 3 SO 3 - .
• the second step can be conducted, for example, by mixing the reaction mixture after completion of the first step or the isolated iminium salt (I) with a phthalimidating agent in a solvent.
• a phthalimidating agent in a solvent.
• a method of adding dropwise the reaction mixture after completion of the first step to the phthalimidating agent is preferable.
• a phthalimide salt is used as the phthalimidating agent.
• phthalimide potassium salt examples thereof include phthalimide potassium salt, phthalimide sodium salt and phthalimide triethylamine salt, among which phthalimide potassium salt is preferred.
• the amount of the phthalimidating agent is preferably from 1 to 10 g equivalents based on 1 g equivalent of the (Z)-hydroxymethylcyclopropane compound (1 g equivalent of the iminium salt (I), assuming that the yield of the iminium salt (I) in the first step is 100%) that is used in the first step, and more preferably from 1 to 2 g equivalents, in view of completion of the reaction or reaction efficiency.
• the phthalimide salt may be produced from phthalimide and a base in a reaction system.
• the base include at least one kind of potassium tert-butoxide, sodium methoxide, potassium carbonate, triethylamine and the like.
• the amount of the base is preferably from 1 to 10 g equivalents, and more preferably from 1 to 2 g equivalents, based on 1 g equivalent of phthalimide.
• the second step is preferably conducted in a solvent.
• the solvent include single solvents and mixed solvents such as aprotic polar organic solvents (such as N,N-dimethylformamide, N,N-dimethylacetoamide, N,N'-dimethylimidazolidinone and N-methyl pyrrolidone) and protic organic solvents (such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, ethylene glycol and propylene glycol), among which aprotic polar organic solvents are preferred in view of reactivity, and N,N-dimethylformamide and N,N-dimethylacetoamide are particularly preferred.
• the amount of the solvent is preferably from 1 to 50 parts by weight based on 1 part by weight of the (Z) -hydroxymethylcyclopropane compound that is used in the first step.
• the reaction temperature of the second step is generally from 0 to 150°C, and preferably from 20 to 80°C.
• the reaction time is generally from 1 to 20 hours, and preferably from 1 to 5 hours.
• the (Z) -phthalimidomethylcyclopropane compound can be isolated and purified by a conventional method.
• isolation can be conducted by adding water or the like to the reaction mixture, filtering and washing the precipitated crystal, or extracting the reaction mixture with an organic solvent, followed by washing with water, and concentration.
• purification may be conducted by crystallization or chromatography.
• the (Z)-aminomethylcyclopropane compound hydrochloride which is useful as an antidepresent, can be derived from the (Z)-phthalimidomethylcyclopropane compound obtained by the present invention by a known method.
• the (Z)-aminomethylcyclopropane compound hydrochloride can be derived by reacting the (Z)-phthalimidomethylcyclopropane compound with an aqueous methylamine solution to obtain the (Z)-aminomethylcyclopropane compound, and treating the compound with hydrogen chloride.
• the (Z)-hydroxymethylcyclopropane compound is a known compound, and as described in JPH02-262558-A , for example, the compound can be produced by reacting 2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane (see Synthesis, 1978, 304-305 ) with diethylamine in the presence of a Lewis acid amine complex.
• a low boiling point halogenated hydrocarbon such as dichloroethane is required in this method, there arises an environmental problem similarly to the above described conventional process for producing the (Z)-phthalimidomethylcyclopropane compound.
• the method can be conducted, for example, by mixing 2-oxo-1-phenyl-3-oxabicyclo[3.1.0] hexane, diethylamine and an alkali metal alkoxide in a solvent.
• the amount of diethylamine is generally from 1 to 10 g equivalents, and preferably from 2 to 4 g equivalents, based only equivalent of 2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane.
• alkali metal alkoxide examples include alkali metal salts of an alcohol having 1 to 4 carbon atoms, such as lithium methoxide, sodium methoxide, potassium methoxide, lithium ethoxide, sodium ethoxide, potassium ethoxide, sodium t-butoxide and potassium t-butoxide.
• Sodium methoxide or potassium methoxide is preferred, and sodium methoxide is particularly preferred.
• the amount of the alkali metal alkoxide is generally from 1 to 5 g equivalents, and preferably from 1.5 to 4 g equivalents, based on 1 g equivalent of 2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane.
• the form of the alkali metal alkoxide is not particularly limited, and it may be in the form of solid or solution.
• a solution of the alcohol solvent corresponding to an alkali metal alkoxide to be used (for example, sodium methoxide in methanol) is preferably selected.
• the alcohol solvent is contained as a portion of a reaction solvent.
• the kind of the solvent to be used is not limited as long as it does not inhibit the reaction, and examples thereof include methanol, ethanol, toluene, hexane, heptane and the like. These solvents can be used alone or in combination.
• the amount of the solvent is generally from 1 to 10 ml, and preferably from 3 to 5 ml, based on 1 g of 2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane.
• the reaction temperature is generally from 0 to 100°C, preferably from 20 to 80°C, and particularly preferably from 20 to 30°C, and the reaction time is generally from 3 to 30 hours, although it varies depending on the reaction amount, the reaction temperature or the like.
• the (Z)-hydroxymethylcyclopropane compound can be obtained by any of known isolation or purification methods in the field or in combination thereof, such as extraction with a solvent, silica gel column chromatography, high performance liquid chromatography, distillation under reduced pressure and recrystallization.
• phthalimide potassium salt (18.7 g, 0.101 mol) and 92 ml of N, N-dimethylformamide were charged in a reaction vessel, and the afore-mentioned concentrated solution was added dropwise to the obtained solution at 40°C over 2 hours, followed by stirring for one hour.
• a concentrated solution before conducting phthalimidation was produced in the same manner as in Example 1, and some of the concentrated solution was taken and evaporated to dryness under reduced pressure. After adding n-heptane to the residue, a decantation operation was repeated several times, followed by evaporation to dryness under reduced pressure to obtain the title compound as a water-soluble pale yellow oil (purity: 98. 6%) .
• a chlorination agent which generates sulfur dioxide during the reaction, is not required because a chloro compound or an acid chloride is not by way of the reaction, unlike a conventional method. Furthermore, it is not required to use a low boiling point halogenated hydrocarbon solvent such as dichloroethane, which may cause an environmental problem.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Indole Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Furan Compounds (AREA)

Applications Claiming Priority (3)

Publications (3)

Family

ID=36740567

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (8)

Family Cites Families (3)

• 2005
  • 2005-05-18 JP JP2005145875A patent/JP4828863B2/ja active Active
• 2006
  • 2006-01-26 DE DE602006021397T patent/DE602006021397D1/de active Active
  • 2006-01-26 CN CN2006800027703A patent/CN101107228B/zh not_active Expired - Fee Related
  • 2006-01-26 ZA ZA200706196A patent/ZA200706196B/xx unknown
  • 2006-01-26 EP EP06712854A patent/EP1845084B1/en active Active
  • 2006-01-26 AT AT06712854T patent/ATE506346T1/de active
  • 2006-01-26 WO PCT/JP2006/301711 patent/WO2006080555A1/ja active Application Filing
  • 2006-01-26 PT PT06712854T patent/PT1845084E/pt unknown
  • 2006-01-26 KR KR1020077019056A patent/KR20070115896A/ko not_active Application Discontinuation
  • 2006-01-26 AU AU2006209453A patent/AU2006209453B2/en not_active Ceased
  • 2006-01-26 CA CA002594721A patent/CA2594721A1/en not_active Abandoned
• 2007
  • 2007-01-26 US US11/795,860 patent/US7943785B2/en not_active Expired - Fee Related
  • 2007-07-01 IL IL184338A patent/IL184338A/en not_active IP Right Cessation
• 2011
  • 2011-02-10 US US13/024,921 patent/US20110130576A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events